About Sol-Gel Technologies
Sol-Gel Technologies is a company based in United States founded in 1998 by Alon Seri-Levy and David Avnir.. Sol-Gel Technologies has raised $9 million across 8 funding rounds from investors including National Science Foundation. The company has 34 employees as of December 31, 2024. Sol-Gel Technologies has completed 1 acquisition, including Patidegib. Sol-Gel Technologies operates in a competitive market with competitors including Revance Therapeutics, Dermavant, SkinMedica, Hugel and Collplant, among others.
- Headquarter United States
- Employees 34 as on 31 Dec, 2024
- Founders Alon Seri-Levy, David Avnir
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sol-Gel Technologies Ltd.
-
Annual Revenue
$11.54 M642.47as on Dec 31, 2024
-
Net Profit
$-10.58 M61.16as on Dec 31, 2024
-
EBITDA
$-11.78 M59.4as on Dec 31, 2024
-
Total Equity Funding
$9 M (USD)
in 8 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Apr 13, 2020
- Investors
-
Employee Count
34
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sol-Gel Technologies
Sol-Gel Technologies is a publicly listed company on the NASDAQ with ticker symbol SLGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of Sol-Gel Technologies
Sol-Gel Technologies has successfully raised a total of $9M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(16 Oct 2007)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Post-IPO - Sol-Gel Technologies | Valuation |
investors |
|
| May, 2009 | Amount | Grant - Sol-Gel Technologies | Valuation |
investors |
|
| Jan, 2009 | Amount | Grant - Sol-Gel Technologies | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sol-Gel Technologies
Sol-Gel Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sol-Gel Technologies
Sol-Gel Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Patidegib. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer therapy drug development services are provided by Patidegib.
|
0 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Sol-Gel Technologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sol-Gel Technologies Comparisons
Competitors of Sol-Gel Technologies
Sol-Gel Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, SkinMedica, Hugel and Collplant, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Skin care products are developed and manufactured by SkinMedica.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
|
| domain | founded_year | HQ Location |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sol-Gel Technologies
Frequently Asked Questions about Sol-Gel Technologies
When was Sol-Gel Technologies founded?
Sol-Gel Technologies was founded in 1998 and raised its 1st funding round 9 years after it was founded.
Where is Sol-Gel Technologies located?
Sol-Gel Technologies is headquartered in United States.
Who is the current CEO of Sol-Gel Technologies?
Alon Seri-Levy is the current CEO of Sol-Gel Technologies. They have also founded this company.
Is Sol-Gel Technologies a funded company?
Sol-Gel Technologies is a funded company, having raised a total of $9M across 8 funding rounds to date. The company's 1st funding round was a Grant of $99.1K, raised on Oct 16, 2007.
How many employees does Sol-Gel Technologies have?
As of Dec 31, 2024, the latest employee count at Sol-Gel Technologies is 34.
What is the annual revenue of Sol-Gel Technologies?
Annual revenue of Sol-Gel Technologies is $11.54M as on Dec 31, 2024.
What does Sol-Gel Technologies do?
Sol-Gel is a clinical-stage specialty pharma focused on developing topical dermatological drug products. Its drug pipeline includes VERED (Phase 2), a topical encapsulated benzoyl peroxide cream for the treatment of papulopustular rosacea; TWIN (Phase 2), a non-antibiotic topical cream and SIRS-T (PreclinicalPhase 1), a topical encapsulated tretinoin cream for the treatment of acne vulgaris E-06 (preclinicalphase 1), a cream formulation of a new fixed-dose combination, containing an antifungal agent and a mid-potency steroid for the treatment of symptomatic c(athletes foot). All its products are based on its proprietary microencapsulation delivery system.
Who are the top competitors of Sol-Gel Technologies?
Sol-Gel Technologies's top competitors include Revance Therapeutics, Dermavant and Collplant.
Is Sol-Gel Technologies publicly traded?
Yes, Sol-Gel Technologies is publicly traded on NASDAQ under the ticker symbol SLGL.
How many acquisitions has Sol-Gel Technologies made?
Sol-Gel Technologies has made 1 acquisition, including Patidegib.
Who are Sol-Gel Technologies's investors?
Sol-Gel Technologies has 1 investor. Key investors include National Science Foundation.
What is Sol-Gel Technologies's ticker symbol?
The ticker symbol of Sol-Gel Technologies is SLGL on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.